Alcohol Addiction – Pipeline Review, H1 2019 –

March 22, 2019 Off By BusinessWire

Addiction – Pipeline Review, H1 2019”
drug pipelines has been
added to’s offering.

This latest Pharmaceutical and Healthcare disease pipeline guide, Alcohol
Addiction – Pipeline Review, H1 2019
, provides an overview of the
Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on
alcohol. Symptoms include decreased involvement in extracurricular
activities, depression, restlessness, inability to control drinking and
violent behavior. Risk factors include age, family history and
depression and other mental health problems.

Report Highlights

This latest pipeline guide Alcohol Addiction – Pipeline Review, H1 2019,
provides comprehensive information on the therapeutics under development
for Alcohol Addiction (Central Nervous System), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also
reviews of key players involved in therapeutic development for Alcohol
Addiction and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase
II, Phase I, Preclinical and Unknown stages are 1, 9, 7, 20 and 1
respectively. Similarly, the Universities portfolio in Preclinical
stages comprises 4 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Alcohol Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alcohol Addiction
    (Central Nervous System) by companies and universities/research
    institutes based on information derived from company and
    industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
  • The pipeline guide reviews key companies involved in Alcohol Addiction
    (Central Nervous System) therapeutics and enlists all their major and
    minor projects.
  • The pipeline guide evaluates Alcohol Addiction (Central Nervous
    System) therapeutics based on mechanism of action (MoA), drug target,
    route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Alcohol Addiction (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Alcohol Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Alcohol Addiction (Central Nervous System) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Key Topics Covered

  1. Introduction
  2. Alcohol Addiction – Overview
  3. Alcohol Addiction – Therapeutics Development
  4. Alcohol Addiction – Therapeutics Assessment
  5. Alcohol Addiction – Companies Involved in Therapeutics Development
  6. Alcohol Addiction – Drug Profiles
  7. Alcohol Addiction – Dormant Projects
  8. Alcohol Addiction – Discontinued Products
  9. Alcohol Addiction – Product Development Milestones
  10. Appendix

Companies Mentioned

  • AbbVie Inc
  • Adial Pharmaceuticals Inc
  • Arbor Pharmaceuticals LLC
  • AstraZeneca Plc
  • BioCorRx Inc
  • Bioprojet SCR
  • Chronos Therapeutics Ltd
  • Confluence Pharmaceuticals LLC
  • Corcept Therapeutics Inc
  • Curemark LLC
  • Eli Lilly and Co
  • Kinnov Therapeutics SAS
  • Kyorin Pharmaceutical Co Ltd
  • Lohocla Research Corp
  • Mapreg SAS
  • Montisera Ltd
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Osmotica Pharmaceutical Corp
  • Pfizer Inc
  • Silence Therapeutics Plc
  • SK Biopharmaceuticals Co Ltd
  • Sosei Heptares
  • Syntropharma Ltd
  • Tonix Pharmaceuticals Holding Corp
  • Zynerba Pharmaceuticals Inc

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Addiction
Disorders Drugs